Entering text into the input field will update the search result below

Life Science Instrumentation Market | Thermo Fisher Scientific Holds The Position In The Market

Sep. 23, 2020 10:29 AM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Summary

  • The global life science instrumentation market size is projected to reach USD 79.9 billion by 2025 from USD 60.0 billion in 2020, growing at a CAGR of 5.9%.

The report "Life Science Instrumentation Market by Technology [Spectroscopy, Chromatography, Flow Cytometry, NGS, PCR,, Microscopy], Application (Research, Clinical), End User (Pharma-Biotech, Agri and Food Industry, Hospitals & Diagnostic Labs) - Global Forecasts to 2025" The global life science instrumentation market size is projected to reach USD 79.9 billion by 2025 from USD 60.0 billion in 2020, growing at a CAGR of 5.9% during the forecast period.

North America to dominate the life science instrumentation market during the forecast period

The life science instrumentation industry is segmented into five regional segments, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North American region accounted for the largest share of the life science instrumentation market in 2019.

Download a PDF Brochure @ Life Science Instrumentation Market

The high adoption rate of novel technologies and the large number of life science research studies conducted in this region. Moreover, stringent drug development regulations, increased funding for life science research activities, and the growing number of metabolomics research studies are some of the major factors driving the growth of the life science instrumentation sector in North America.

Key Market Players

The vendors operating in the global life science instrumentation market include Agilent Technologies (US), Becton, Dickinson, and Company (US), Bio-Rad Laboratories, Inc. (US), Bruker Corporation (US), Danaher Corporation (US), Eppendorf AG (Germany), GE Healthcare (US), Hitachi High-Technologies Corporation (Japan), Horiba (Japan), Merck KGaA (Germany), PerkinElmer, Inc. (US), Qiagen N.V. (Netherlands), Shimadzu Corporation (Japan), Thermo Fisher Scientific, Inc. (US), and Waters Corporation (US).

An analysis of the market developments between 2017 and 2020 revealed that several growth strategies such as product launches & enhancements, partnerships, and strategic acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the life science instrumentation market. Among these business strategies, product approval & launches, acquisition, partnerships, and agreements were the most widely adopted growth strategies by market players.

Thermo Fisher Scientific, Inc. holds the leading position in the global life science instrumentation market, owing to its robust portfolio of life science instruments products and related accessories. Thermo Fisher has expanded its product portfolio through insight-driven innovation and strategic M&A to address to establish its position in the market.

Request a Sample Pages @ Life Science Instrumentation Market

For instance, during the last three years. Thermo Fisher launched several instruments, such as the Biosystems QuantStudio 6 and 7 Pro Real-Time PCR Systems (April 2019), the Vanquish Duo UHPLC system, Scientific Q Exactive UHMR mass spectrometer, and Ion GeneStudio S5 Series next-generation sequencing systems (February 2018), and ISQ EC Single Quadrupole mass spectrometer (June 2017). The company further offers its products across major customer categories, such as clinical laboratories, research & academic institutes, diagnostic laboratories, and hospitals. Thermo Fisher is expected to witness sustainable growth during the forecast period with its broad and technologically advanced product portfolio, wide geographic reach, and collaborations, agreements with other smaller market players

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.